[Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].
Behçet's disease (BD) is chronic, relapsing and multisystem inflammatory disorder, whose diagnosis is essentially clinical. In recent studies, the antagonists of tumor necrosis factor alpha have shown good results in the treatment of mucocutaneous manifestations of BD. The authors describe three cases of BD with serious mucocutaneous involvement treated with infliximab. CLINICAL CASE 1: A 16-year-old female patient with an 8-year history of severe bipolar aphtosis. A rapid clinical response to biological therapy was verified, with partial and total remission of ulcers at 2nd and 6th week of treatment, respectively. CLINICAL CASE 2: A 56-year-old female patient with chronic nodular panniculitis of lower limbs, arthralgias and orogenital ulceration. After 6 weeks of treatment with infliximab, a complete clinical remission was observed. CLINICAL CASE 3: A 50-year-old female with a 15-year history of relapsing oropharyngeal ulceration. A good clinical response to biologic therapy was observed. At 22nd week it was interrupted because frequent dental abscesses. In our experience, infliximab is an effective therapeutic alternative that should be considered in the presence of mucocutaneous manifestations resistant to conventional therapies.
Lestre
Sara
S
Internato Complementar de Dermatovenereologia, Serviço de Dermatologia, Hospital de Santo António dos Capuchos, Alameda Santo António dos Capuchos, Lisboa. saralestre@netcabo.pt
Trindade
Felicidade
F
Martins
Andrea
A
Baptista
Juliana
J
Feio
Ana Barata
AB
Lopes
Maria João Paiva
MJ
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications*; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D009092:Mucous Membrane; D019226:Oral Ulcer / Q000188:drug therapy* / Q000209:etiology; D012883:Skin Ulcer / Q000188:drug therapy* / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014456:Ulcer / Q000188:drug therapy* / Q000209:etiology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab